110 results
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
22 Dec 21
Alvelestat reported safe and well-tolerated in patients with COVID-19
7:45am
study in adult patients (>18 years) with COVID-19 Respiratory Disease, evaluating the safety and tolerability of alvelestat on top of Standard of Care … escalation to evaluate safety and tolerability for the population. The Primary Endpoint was Safety and Tolerability to Day 60, with mortality assessment
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
9 May 22
Current report (foreign)
8:06am
Exhibit 99.1
Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin … at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease
No safety signals were associated with alvelestat
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
14 Mar 22
Current report (foreign)
10:05am
relating to unanticipated costs, liabilities or delays; failure or delays in research and development programs; the safety and efficacy … and is complementary to ASTRAEUS Alvelestat has demonstrated a clean safety profile in all studies to-date with a tendency for headaches managed through dose
6-K
MREO
Mereo Biopharma Group Plc
9 May 22
Current report (foreign)
8:06am
Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema
On May 9, 2022, Mereo … BioPharma Group plc (the “Company”) announced positive top-line efficacy and safety results from “ASTRAEUS” a Phase 2 study of the investigational oral
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
30 Nov 21
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of
7:51am
analysis set
Etigilimab was well tolerated with a favorable safety profile
Conference call today at 8:30am ET
London and Redwood City, Calif … and rare diseases, today reported promising interim efficacy, safety, and biomarker data on patients from ACTIVATE, a Phase 1b/2 study of its anti-TIGIT
6-K
EX-99.1
08pu1h0
25 Aug 20
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
11:14am
6-K
EX-99.1
qtyrsbruj48n3
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.1
xiqemt
22 Nov 19
Current report (foreign)
9:29am
F-1/A
e5agvc1z
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
6-K
EX-99.1
usdbpk
2 Jun 22
Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
9:07am
F-1/A
oc1sm07
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
l89khth2s
15 Jul 19
Current report (foreign)
9:27am
10-K
w3x9k 6ctezp4h6g
27 Mar 24
Annual report
5:20pm
20-F
5zogjovesh9
29 Apr 19
Annual report (foreign)
4:59pm
6-K
rh9m9lz9xygnk51rrmkd
21 Jun 19
Current report (foreign)
11:10am
6-K
EX-99.1
341ilpftxv
26 May 22
Current report (foreign)
5:11pm
6-K
b7kfu7
20 Jun 19
Current report (foreign)
6:56am
6-K
ti3rxbvwbriwc
16 Jul 19
Current report (foreign)
8:21am
6-K
EX-99.1
q6qs dpmx
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
z1chfw3
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm